CN102827281A - 抗cd2蛋白单克隆抗体及其用途 - Google Patents
抗cd2蛋白单克隆抗体及其用途 Download PDFInfo
- Publication number
- CN102827281A CN102827281A CN201210274519XA CN201210274519A CN102827281A CN 102827281 A CN102827281 A CN 102827281A CN 201210274519X A CN201210274519X A CN 201210274519XA CN 201210274519 A CN201210274519 A CN 201210274519A CN 102827281 A CN102827281 A CN 102827281A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- cell
- protein
- chip
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 title abstract description 41
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 title abstract description 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 230000002055 immunohistochemical effect Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 13
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000003531 protein hydrolysate Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000008025 CLOCK Proteins Human genes 0.000 description 2
- 108010075228 CLOCK Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 101150069832 CD2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100256844 Mus musculus Sgpl1 gene Proteins 0.000 description 1
- 101000868474 Mus musculus Sialoadhesin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710165202 T-cell surface antigen CD2 Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000000690 anti-lymphoma Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical class [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210274519.XA CN102827281B (zh) | 2012-08-03 | 2012-08-03 | 抗cd2蛋白单克隆抗体及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210274519.XA CN102827281B (zh) | 2012-08-03 | 2012-08-03 | 抗cd2蛋白单克隆抗体及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102827281A true CN102827281A (zh) | 2012-12-19 |
CN102827281B CN102827281B (zh) | 2014-05-28 |
Family
ID=47330614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210274519.XA Active CN102827281B (zh) | 2012-08-03 | 2012-08-03 | 抗cd2蛋白单克隆抗体及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102827281B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020236795A2 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2021195513A1 (en) | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
WO2022097061A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1288950A (zh) * | 1999-09-22 | 2001-03-28 | 上海复星高科技(集团)有限公司 | 以dna免疫为基础的单克隆抗体的制备方法及其应用 |
CN1507354A (zh) * | 2001-03-02 | 2004-06-23 | ͨ��ҽ�ƹ�˾ | 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法 |
CN1771055A (zh) * | 2002-09-05 | 2006-05-10 | 免疫医疗公司 | 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法 |
-
2012
- 2012-08-03 CN CN201210274519.XA patent/CN102827281B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1288950A (zh) * | 1999-09-22 | 2001-03-28 | 上海复星高科技(集团)有限公司 | 以dna免疫为基础的单克隆抗体的制备方法及其应用 |
CN1507354A (zh) * | 2001-03-02 | 2004-06-23 | ͨ��ҽ�ƹ�˾ | 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法 |
CN1771055A (zh) * | 2002-09-05 | 2006-05-10 | 免疫医疗公司 | 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020236795A2 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2021195513A1 (en) | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
WO2022097061A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102827281B (zh) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9823251B2 (en) | Anti-Uroplakin II antibodies systems and methods | |
CN102827281B (zh) | 抗cd2蛋白单克隆抗体及其用途 | |
CN106978400A (zh) | 抗pd‑l1蛋白单克隆抗体及其用途 | |
CN105238762A (zh) | 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用 | |
CN111848750B (zh) | 一种快速富集和检测2019-nCoV的方法及试剂盒 | |
CN106188292B (zh) | 抗cd4蛋白单克隆抗体及其用途 | |
CN105254759A (zh) | 抗cd56蛋白单克隆抗体杂交瘤细胞及其产生的抗cd56单克隆抗体和应用 | |
CN105131114B (zh) | 抗p16蛋白单克隆抗体杂交瘤细胞及其产生的抗p16单克隆抗体和应用 | |
CN102924594B (zh) | 抗肿瘤蛋白p63单克隆抗体及其用途 | |
CN103102414B (zh) | 抗her2蛋白单克隆抗体及其用途 | |
CN102786595B (zh) | 抗cd5蛋白单克隆抗体及其用途 | |
JP2021503014A (ja) | 牛妊娠関連グリコタンパク質1に特異的に結合する抗体及びその用途 | |
CN107188965A (zh) | 抗dog1蛋白单克隆抗体及其用途 | |
CN110357964A (zh) | 抗cd31蛋白单克隆抗体及其用途 | |
CN102827278B (zh) | 抗肿瘤蛋白p53单克隆抗体及其用途 | |
CN109021102A (zh) | 抗sma蛋白单克隆抗体及其用途 | |
CN106749668A (zh) | 抗ido1蛋白单克隆抗体及其用途 | |
CN106977605A (zh) | 抗cd19蛋白单克隆抗体及其用途 | |
CN106854245A (zh) | 抗cd30蛋白单克隆抗体及其用途 | |
CN107266572A (zh) | 抗pd‑l1蛋白单克隆抗体及其用途 | |
CN105622751B (zh) | 抗Ki67蛋白单克隆抗体及其用途 | |
CN105237638A (zh) | 抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用 | |
CN102911271B (zh) | 抗ctnnb1单克隆抗体12h7及其用途 | |
CN102898520B (zh) | 抗ctnnb1单克隆抗体3f9及其用途 | |
CN105238763A (zh) | 抗pr蛋白单克隆抗体杂交瘤细胞及其产生的抗pr单克隆抗体和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160125 Address after: 100084 room 0112-116, room, No. 26, Haidian District Road, Beijing Patentee after: EDIGENE Inc. Address before: 214092, Jiangsu province Wuxi Binhu District Mashan biological medicine outsourcing Area No. 7, building two, 2 floor Patentee before: WUXI ORIGENE BIO-TECHNOLOGY CO.,LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Monoclonal antibodies against CD2 protein and their applications Effective date of registration: 20231128 Granted publication date: 20140528 Pledgee: Beijing Zhongguancun bank Limited by Share Ltd. Pledgor: EDIGENE Inc. Registration number: Y2023990000579 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |